Dyadic International (NASDAQ:DYAI) Posts Quarterly Earnings Results

Dyadic International (NASDAQ:DYAI) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02), FiscalAI reports. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.02 million.

Dyadic International Stock Performance

Shares of Dyadic International stock traded down $0.16 during trading on Wednesday, hitting $0.89. 316,690 shares of the stock were exchanged, compared to its average volume of 180,259. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The company has a fifty day moving average price of $0.96 and a 200-day moving average price of $0.86. The stock has a market capitalization of $32.42 million, a price-to-earnings ratio of -3.87 and a beta of 1.12. Dyadic International has a 1-year low of $0.65 and a 1-year high of $1.60.

Hedge Funds Weigh In On Dyadic International

A number of hedge funds and other institutional investors have recently bought and sold shares of DYAI. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the third quarter valued at approximately $190,000. Finally, Geode Capital Management LLC lifted its position in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the last quarter. Institutional investors own 27.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.